Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Fantone, S; Piani, F; Olivieri, F; Rippo, MR; Sirico, A; Di, Simone, N; Marzioni, D; Tossetta, G.
Role of SLC7A11/xCT in Ovarian Cancer.
Int J Mol Sci. 2024; 25(1):
Doi: 10.3390/ijms25010587
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
- Authors Med Uni Graz:
- Piani Federica
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Ovarian cancer is one of the most dangerous gynecologic cancers worldwide and has a high fatality rate due to diagnosis at an advanced stage of the disease as well as a high recurrence rate due to the occurrence of chemotherapy resistance. In fact, chemoresistance weakens the therapeutic effects, worsening the outcome of this pathology. Solute Carrier Family 7 Member 11 (SLC7A11, also known as xCT) is the functional subunit of the Xc- system, an anionic L-cystine/L-glutamate antiporter expressed on the cell surface. SLC7A11 expression is significantly upregulated in several types of cancers in which it can inhibit ferroptosis and favor cancer cell proliferation, invasion and chemoresistance. SLC7A11 expression is also increased in ovarian cancer tissues, suggesting a possible role of this protein as a therapeutic target. In this review, we provide an overview of the current literature regarding the role of SLC7A11 in ovarian cancer to provide new insights on SLC7A11 modulation and evaluate the potential role of SLC7A11 as a therapeutic target.
- Find related publications in this database (using NLM MeSH Indexing)
- Female - administration & dosage
- Humans - administration & dosage
- Ovarian Neoplasms - drug therapy
- Genital Neoplasms, Female - administration & dosage
- Antiporters - administration & dosage
- Cell Membrane - administration & dosage
- Glutamic Acid - administration & dosage
- Amino Acid Transport System y+ - genetics